Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

First randomized trial on adjuvant mitotane in adrenocortical carcinoma...

Prof Alfredo Berruti - University Of Brescia, Brescia, Italy

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. ( Prof Alfredo Berruti - University Of Brescia, Brescia, Italy )

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible...

Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer ( Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Update on the new EUSOMA quality indicators for breast cancer

Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal

Update on the new EUSOMA quality indicators for breast cancer ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )

The optimal approach after neoadjuvant treatment: The Lucerne toolbox

Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal

The optimal approach after neoadjuvant treatment: The Lucerne toolbox ( Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal )

Tumour agnostic treatments in GI cancer

Dr Nicola Normanno and Dr Katja Schmitz

Tumour agnostic treatments in GI cancer ( Dr Nicola Normanno and Dr Katja Schmitz )

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs...

Prof Peter Schmid - Queen Mary University of London, London, United Kingdom

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC ( Prof Peter Schmid - Queen Mary University of London, London, United Kingdom )

Durvalumab plus chemotherapy significantly improved OS in advanced biliary...

Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South...

Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer ( Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South Korea )

Early treatment discontinuation and early oxaliplatin discontinuation for stage...

Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France

Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer ( Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France )

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in...

Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC ( Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA )

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant...

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )

Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

More from ecancer